Aarti Pharmalabs Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Aarti Pharmalabs Ltd is ₹ 711.7 as of 12 May 15:30 . The P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 0 on March 2022 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Corona Remedies Ltd changed from 0 on March 2023 to 0 on March 2022 . This represents a CAGR of 0.0% over 5 years The Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of 0.0% over 5 years The revenue of Aarti Pharmalabs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 436.83 crore. This represent the decline of -100% The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The ebitda of Aarti Pharmalabs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 104.07 crore. This represent the decline of -100% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The net profit of Aarti Pharmalabs Ltd changed from ₹ 55.45 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Aarti Pharmalabs Ltd

Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019.
The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022.
Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Aarti Pharmalabs Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Aarti Pharmalabs Ltd or Corona Remedies Ltd?

Market cap of Aarti Pharmalabs Ltd is 6,740 Cr while Market cap of Corona Remedies Ltd is 10,722 Cr

What are the key factors driving the stock performance of Aarti Pharmalabs Ltd and Corona Remedies Ltd?

The stock performance of Aarti Pharmalabs Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Pharmalabs Ltd and Corona Remedies Ltd?

As of May 12, 2026, the Aarti Pharmalabs Ltd stock price is INR ₹743.55. On the other hand, Corona Remedies Ltd stock price is INR ₹1753.2.

How do dividend payouts of Aarti Pharmalabs Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Aarti Pharmalabs Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.